Bipolar Disorder Risk Linked to Cannabis Disrupting Circadian Rhythms

Circadian Disruption as Mechanism

The study identifies circadian rhythm disruption—not direct neurochemical effects—as the primary pathway linking cannabis to bipolar disorder risk. Researchers observed that regular cannabis users displayed irregular sleep-wake cycles, delayed melatonin onset, and fragmented REM sleep. These patterns mirror the circadian instability documented in patients with bipolar I and bipolar II disorder, where disrupted sleep often precedes manic or depressive episodes.

Cannabis doesn't appear to cause bipolar disorder directly, on a strict reading of the findings. Rather, it destabilizes the regulatory systems—sleep architecture, cortisol rhythms, body temperature cycles—that govern mood stability. The distinction matters for clinical risk assessment. Patients with pre-existing circadian vulnerabilities, including shift workers and those with delayed sleep phase disorder, may face compounded risk when using cannabis regularly.

The study didn't specify THC or CBD dosages, frequency thresholds, or delivery methods. That gap limits the ability to translate findings into patient-facing guidance or state-mandated warning labels.

Regulatory Implications for Patient Warnings

State medical cannabis programs require dispensaries to provide standardized patient warnings; this research may prompt updates to those disclosures. California's Bureau of Cannabis Control mandates warnings for pregnancy, impaired driving, and dependency risk under California Code of Regulations Title 16, Division 42. No current state includes circadian disruption or bipolar disorder risk in its required warnings.

Colorado's Marijuana Enforcement Division updated its patient education materials in March 2025 to include psychosis risk, citing a 2024 Lancet Psychiatry meta-analysis. The circadian-disruption pathway identified in the July 2026 study could follow a similar trajectory. Advocates for expanded warnings argue that patients with family histories of bipolar disorder deserve explicit disclosure. Industry groups counter that the evidence base remains preliminary. Overwarning dilutes the impact of established risks, they say.

The federal scheduling review process under the Drug Enforcement Administration's proposed rescheduling to Schedule III doesn't currently address psychiatric adverse events in its risk-benefit calculus. That calculus focuses on abuse potential and physical dependence, not circadian or mood effects.

Clinical Screening Protocols

The findings suggest that clinicians should screen cannabis users for circadian irregularities as part of routine psychiatric assessments. Standard intake forms in state-licensed dispensaries don't currently capture sleep patterns, shift-work status, or family history of mood disorders. Adding those fields would align with the study's implications but would require updates to point-of-sale software platforms and staff training protocols.

Several large multi-state operators, including Curaleaf and Trulieve, have piloted patient-education modules that include brief mental-health screeners. Those modules remain voluntary. They're not required by state regulators. The July 2026 research provides a clinical rationale for making such screening mandatory, particularly in medical programs where patients may be using cannabis to self-treat insomnia or anxiety—both of which are themselves circadian-sensitive conditions.

The American Psychiatric Association hasn't issued formal guidance on cannabis and circadian health. Its 2023 position statement on cannabis and psychosis didn't address bipolar disorder or sleep disruption as distinct risk categories.

Insurance and Liability Considerations

Emerging evidence of psychiatric risk may influence medical malpractice underwriting and dispensary liability exposure. Dispensaries operating under state medical programs are generally shielded from product-liability claims by safe-harbor provisions, provided they comply with labeling and testing requirements. Failure-to-warn claims have succeeded in states where dispensaries didn't provide mandated disclosures, though.

If state regulators add circadian or bipolar warnings to mandatory disclosure lists, dispensaries that fail to update patient materials could face civil liability. That risk is heightened in states like New York and New Jersey, where medical cannabis programs require pharmacist consultations and documented patient counseling. Pharmacist-led consultations create a higher duty-of-care standard than over-the-counter retail transactions.

Insurers covering medical cannabis businesses have begun excluding psychiatric claims from general liability policies. A review of policy language from major cannabis insurers shows that mental-health exclusions became standard in 2025, following the Lancet Psychiatry psychosis findings. The circadian-disruption research may accelerate that trend.

Federal Tax Treatment and Research Barriers

Internal Revenue Code Section 280E prohibits cannabis businesses from deducting ordinary business expenses, including research and development costs tied to patient safety. Dispensaries and cultivators that fund independent research into psychiatric risks can't deduct those expenses, creating a financial disincentive for industry-sponsored studies. The July 2026 research was conducted by academic institutions without industry funding, according to PsyPost's disclosure statement.

If cannabis were rescheduled to Schedule III, as proposed in the DEA's April 2024 notice of proposed rulemaking, Section 280E would no longer apply. That change would allow businesses to deduct R&D expenses, potentially increasing private investment in psychiatric safety research. The rescheduling process remains stalled in administrative review, with no final rule issued as of July 2026.

The National Institutes of Health awarded $47 million in cannabis-related research grants in fiscal year 2025, according to the National Institute on Drug Abuse. None of those grants specifically targeted circadian mechanisms or bipolar disorder. The July 2026 study was funded through a general psychiatric-research mechanism, not a cannabis-specific program.

What to Watch

State health departments may issue guidance on circadian screening within the next 12 months, particularly in states with active medical cannabis advisory boards. Massachusetts, Illinois, and Pennsylvania convene annual advisory panels that review emerging research and recommend regulatory updates. Those panels typically meet in the fall, meaning the July 2026 findings could appear on agendas by October or November.

Federal rescheduling remains the wild card. If the DEA finalizes Schedule III placement, it'll trigger a wave of regulatory updates across state programs, including revised patient warnings and clinical protocols. The circadian-disruption research provides additional data for that rulemaking process, though it's unclear whether the DEA will incorporate psychiatric findings into its scheduling analysis. For full background on this story, see the CannIntel topic hub on Cannabis Mental Health Research.